Adaptive Biotechnologies (ADPT) Depreciation & Amortization (CF) (2018 - 2026)

Adaptive Biotechnologies has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $3.4 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 21.0% year-over-year to $3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 11.0% YoY) and the FY2025 annual result came in at $16.0 million, down 8.26% from the prior year.
• Depreciation & Amortization (CF) declined to $3.4 million in Q1 2026 per ADPT's latest filing, from $3.7 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $5.3 million in Q3 2023 and troughed at $3.4 million in Q1 2026.
• A 5-year average of $4.5 million and a median of $4.6 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) surged 105.91% in 2022, then retreated 22.1% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $4.9 million in 2022, then increased by 1.52% to $4.9 million in 2023, then retreated by 20.28% to $3.9 million in 2024, then dropped by 7.1% to $3.7 million in 2025, then fell by 7.28% to $3.4 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.4 million, $3.7 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.